EPI-PHARE publishes an article in Frontiers in Global Women’s Health.
The article sheds light on the increased risk of meningioma associated with medroxyprogesterone acetate (DMPA), an injectable contraceptive used by 74 million women worldwide each year.
Global awareness is needed, particularly in low-income countries where access to diagnosis and neurosurgery may be limited.
The international scientific community should mobilize around the major public health challenge of assessing the risk of meningioma in DMPA users, particularly in low socio-economic countries.